Loading clinical trials...

A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain | Clinical Trials | Clareo Health

RECRUITINGPHASE2

A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain

A Single Arm Phase II Study Assessing Efficacy of Stereotactic Radiosurgery (SRS) for Brain Metastasis (BM) From Small Cell Lung Cancer (SCLC)

NCT05419076•Memorial Sloan Kettering Cancer Center

View on ClinicalTrials.gov

Summary

The purpose of the study is to see if stereotactic radiosurgery/SRS is an effective treatment for people with a new diagnosis of brain metastases from small cell lung cancer/SCLC.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Histologic diagnosis of small cell lung cancer
•Radiographic diagnosis of up to 20 brain metastases on contrast-enhanced MRI
•Age 18 and above
•Performance status KPS 60-100/ECOG 0-2
•Female patients must be of non-reproductive potential or have a negative serum pregnancy test at the time of enrollment
•The patient or legally authorized representative is able to provide informed consent

Exclusion Criteria

•Unable to undergo contrast-enhanced MRI brain
•Leptomeningeal disease confirmed on lumbar puncture, MRI brain, or MRI spine
•Pregnant or lactating women
•Prior brain-directed radiotherapy
•Uncontrolled systemic disease without reasonable systemic therapy options felt likely to result in death as observed on CT or PET/CT imaging, no more than 3 months before study enrollment

Locations (7)

Memorial Sloan Kettering at Basking Ridge

Basking Ridge, New Jersey, United States

Memorial Sloan Kettering Monmouth

Middletown, New Jersey, United States

Memorial Sloan Kettering Bergen

Montvale, New Jersey, United States

Memorial Sloan Kettering Suffolk - Commack

Commack, New York, United States

Memorial Sloan Kettering Westchester

Harrison, New York, United States

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, New York, United States

Memorial Sloan Kettering Nassau

Rockville Centre, New York, United States

Key Dates

Start Date

June 10, 2022

Primary Completion Date

June 10, 2026

Completion Date

June 10, 2026

Last Updated

February 11, 2026

Enrollment

ESTIMATED participants

Conditions

Lung CancerLung Cancer MetastaticBrain MetastasesBrain Metastases, AdultSmall-cell Lung CancerSmall Cell Lung Carcinoma

Interventions

Stereotactic Radiosurgery

RADIATION

Cerebrospinal fluid collection

PROCEDURE

Contacts

Luke Pike, MD

CONTACT

201-775-7604 PikeL@mskcc.org

Brandon Imber, MD

CONTACT

631-212-6346 imberb@mskcc.org

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

NCT07485114

Renal Cell Carcinoma (Kidney Cancer)Non Small Cell Lung Cancer+2 more

View study

RECRUITING

Magnetic Resonance Imaging of the Lung: Oncological Applications

NCT07486219

Lung Cancer (NSCLC)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 11, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain

Inclusion Criteria

Exclusion Criteria

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

Magnetic Resonance Imaging of the Lung: Oncological Applications

Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer